Anti-angiogenic therapy
US8758748B2 · kind B2 · utility
0Cited by
11References
6Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 20, 2010 |
| Grant date | Jun 24, 2014 |
| Priority date | — |
| Expiry date | Sep 9, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides novel monoclonal antibodies directed to PlGF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and/or prevention of pathological angiogenesis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.